Vyxeos (Daunorubicin/Cytarabine Lipos) Patent Expiration, LOE Window & CMS Spending
Vyxeos (Daunorubicin/Cytarabine Lipos) by Jazz Pharmaceuticals: FDA Orange Book LOE 2033-04-15, 0 AB generics, $878K 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Jazz Pharmaceuticals |
| FDA Application & Pathway | N209401 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-04-15 |
| Orange Book Patents (*PED Extensions) | 15 patents (7 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $878K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $878K |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 21.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.